Wire · opportunities
Eli Lilly escalates oral SERD battle with FDA approval for Inluriyo, Verzenio combo
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 September 2026 · Fusion42 review
The FDA approved Eli Lilly's combination of Inluriyo and Verzenio for ER-positive, HER2-negative breast cancer with ESR1 mutations, extending treatment options beyond Inluriyo monotherapy and offering longer progression-free survival.
This Wire brief sits within Fusion42's coverage of Medtech, and 5 sources have reported it between 18 Sep 2026 and 21 Sep 2026.
◆ ◆ The Wire takeaway
You have a clear market lead with Inluriyo-Verzenio’s broader FDA label lifting its use above monotherapy competitors. Watch AstraZeneca’s Etcamah struggles as your proof that proven clinical progression-based treatments still define payer and physician preferences.
◆ Coverage
5 sources · first reported 18 Sep 2026 · latest 21 Sep 2026
◆ Related on Wire
◆ Topics